TCIM
PCRX icon

TIAA CREF Investment Management’s Pacira BioSciences PCRX Stock Holding History

TIAA CREF Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$14.5M Buy
380,196
+4,763
+1% +$186K 0.01% 857
2018
Q4 		$16.2M Buy
375,433
+56,230
+18% +$2.62M 0.01% 729
2018
Q3 		$15.7M Buy
319,203
+159,044
+99% +$6.87M 0.01% 854
2018
Q2 		$5.13M Sell
160,159
-6,536
-4% -$226K ﹤0.01% 1580
2018
Q1 		$5.19M Sell
166,695
-28,821
-15% -$1.03M ﹤0.01% 1528
2017
Q4 		$8.93M Buy
195,516
+6,597
+3% +$261K 0.01% 1205
2017
Q3 		$7.09M Sell
188,919
-2,305
-1% -$92.8K ﹤0.01% 1395
2017
Q2 		$9.12M Buy
191,224
+55,057
+40% +$2.55M 0.01% 1199
2017
Q1 		$6.21M Buy
136,167
+27,942
+26% +$1.21M ﹤0.01% 1446
2016
Q4 		$3.5M Sell
108,225
-7,063
-6% -$236K ﹤0.01% 1851
2016
Q3 		$3.94K Buy
115,288
+1,776
+2% +$69.6K ﹤0.01% 1763
2016
Q2 		$3.83M Sell
113,512
-1,327
-1% -$65.2K ﹤0.01% 1733
2016
Q1 		$6.08M Sell
114,839
-3,555
-3% -$208K ﹤0.01% 1385
2015
Q4 		$9.09M Sell
118,394
-1,697
-1% -$96.1K 0.01% 1126
2015
Q3 		$4.94M Sell
120,091
-4,139
-3% -$254K ﹤0.01% 1552
2015
Q2 		$8.79M Sell
124,230
-55,722
-31% -$4.39M 0.01% 1246
2015
Q1 		$16M Buy
179,952
+52,479
+41% +$5.32M 0.01% 874
2014
Q4 		$11.3M Sell
127,473
-6,733
-5% -$637K 0.01% 1036
2014
Q3 		$13M Sell
134,206
-1,943
-1% -$189K 0.01% 936
2014
Q2 		$12.5M Buy
136,149
+28,303
+26% +$2.16M 0.01% 1021
2014
Q1 		$7.55M Sell
107,846
-3,368
-3% -$229K 0.01% 1318
2013
Q4 		$6.39M Buy
111,214
+333
+0.3% +$17.5K ﹤0.01% 1454
2013
Q3 		$5.33M Sell
110,881
-1,776
-2% -$64.7K ﹤0.01% 1540
2013
Q2 		$3.27M Buy
+112,657
New +$3.26M ﹤0.01% 1830

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TIAA CREF Investment Management's PCRX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Pacira BioSciences (PCRX) stake by 1.3% in Q1 2019, buying an estimated $186K and bringing the position to 380,196 shares worth $14.5M. The position accounts for 0.01% of the portfolio, ranked #857.

TIAA CREF Investment Management first reported a position in PCRX in Q2 2013 and has held it in 24 quarters since. The position peaked at $16.2M in Q4 2018. 210 funds tracked by Wall St. Rank hold PCRX as of Q1 2019.

  • TIAA CREF Investment Management held 380,196 shares of Pacira BioSciences worth $14.5M as of Q1 2019.
  • TIAA CREF Investment Management bought 4,763 Pacira BioSciences shares in Q1 2019, an estimated $186K.
  • Pacira BioSciences made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #857 holding.
  • TIAA CREF Investment Management first reported a position in Pacira BioSciences in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Pacira BioSciences position peaked at $16.2M in Q4 2018.
  • 210 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.